tbuckley/cabot-search huggingface dataset:
Health‐related quality of life in allergic rhinitis: comparing the short form ESPRINT‐15 and MiniRQLQ questionnaires
Authors: A. Valero, J. Alonso, I. Antépara, E. Baró, C. Colás, A. Del Cuvillo, M. Ferrer, M. Herdman, E. Marti‐Guadaño, L. Monclús, A. M. Navarro‐Pulido, J. Sastre, I. Izquierdo, J. Mullol
Journal: Allergy (2007)

Background: We compared the psychometric properties of the ESPRINT‐15, the short form of a new Spanish instrument to measure health‐related quality of life in allergic rhinitis (AR) patients, with those of the Mini‐Rhinoconjunctivitis Quality of Life Questionnaire (MiniRQLQ). Methods: The questionnaires were compared in Spanish patients with intermittent allergic rhinitis (IAR) or persistent AR in a prospective, observational study. Floor and ceiling effects, internal consistency (Cronbach’s alpha), test–retest reliability (intraclass correlation coefficient; ICC), convergent and known groups validity, and sensitivity to change (standardized response means; SRMs) were compared. Results: In terms of content, while the MiniRQLQ has a dimension covering practical problems and places more emphasis on symptoms, the ESPRINT‐15 has two dimensions (Sleep and Psychological impact) which are not included in the MiniRQLQ. In the validation study, 400 patients were included and 59% of the sample had persistent AR. There were no significant floor or ceiling effects on any dimension on either questionnaire. Cronbach’s alpha values for the ESPRINT‐15 and MiniRQLQ overall scores were 0.92 and 0.90, respectively. In 48 clinically stable patients, ICCs were 0.80 and 0.77, respectively. Both instruments discriminated between patients with IAR and persistent AR. Correlations with symptom scores and generic measures were moderate to strong. SRMs for overall scores and individual dimensions on the two questionnaires in the 197 patients reporting a change in health status ranged from 0.7 to 1.3. Conclusions: Both questionnaires performed well in psychometric terms. The ESPRINT‐15 is particularly recommended for use in Spanish‐speaking populations.
In vitro effect of nanoleakage expression on resin-dentin bond strengths analyzed by microtensile bond test, SEM/EDX and TEM
Authors: M. Hashimoto, J. De Munck, S. Ito, H. Sano, M. Kaga, H. Oguchi, B. Van Meerbeek, D.H. Pashley
Journal: Biomaterials (2004)
Trends in Hospitalization Associated With Traumatic Brain Injury
Authors: David Thurman
Journal: JAMA (1999)

Traumatic brain injury (TBI) is associated with more than 50000 deaths in the United States each year, and recent observations suggest a substantial decline in TBI-related hospitalizations and deaths.To analyze long-term trends in TBI-related hospitalization in the United States.Analysis of existing data from 1980 through 1995 from the National Hospital Discharge Survey, an annual survey representing the US general population. The number of participating hospitals ranged from 400 to 494.Annual rates of TBI-related hospitalization, stratified by age, sex, severity of injury, and outcome.The annual number of TBI cases identified from the sample during the study period ranged from 1611 to 3129. Overall rates of hospitalization for TBI declined an estimated 51%, from 199 to 98 per 100000 per year. When analyzed by severity of injury, mild TBIs declined most during this period, from 130 to 51 hospitalizations per 100000 per year (61% decline; P<.001 compared with intermediate and severe TBI). The decline was greatest among those aged 5-14 years (-66%) and least among those aged 65 years or older (-9%). The ratio of male to female rates showed little variation during the study period (ratio, 1.8; 95% confidence interval [CI], 1.6-2.0), as did the in-hospital mortality rate (mean, 5.3 per 100000; 95% CI, 3.6-7.1).Changes in hospital practices may be a major factor in the declining rates of TBI-related hospital admissions. These practices increasingly appear to exclude persons with less severe TBI from hospital admission and shift their care to outpatient settings.
Failure of heavy chain glycosylation of IgG in some patients with common, variable agammaglobulinemia.
Authors: F Ciccimarra, F S Rosen, E Schneeberger, E Merler
Journal: Journal of Clinical Investigation (1976)

Four patients with common, variable agammaglobulinemia were preveiously reported to have normal numbers of circulating B lymphocytes which synthesized normal amounts of IgG in tissue culture but failed to secrete the newly synthesized IgG. The B lymphocytes of these patients fail to incorporate [3H]mannose and/or [3H]glucosamine into newly synthesized IgG, whereas such incorporation appears to occur just before IgG secretion in cultures of normal B lymphocytes.
Abstract 345: Circulating tumor cells from perfusable tumor nodules grown on decellularized rat lung scaffold has mesenchymal characteristics
Authors: Dhruva K. Mishra, Brandi N. Baird, Harald C. Ott, Don L. Gibbons, Jonathan M. Kurie, Min P. Kim
Journal: Cancer Research (2012)

Abstract Circulating tumor cells are thought to be responsible for metastasis. These cells leave the primary site of cancer and enter the circulation after undergoing epithelial to mesenchymal transition. The tumor cells lose the epithelial features, such as expression of E-cadherin, and acquire mesenchymal characteristics, such as expression of Twist1, Zeb and N-cadherin. In this study, we developed a novel ex vivo model that utilizes a decellularized rat lung scaffold to grow tumor nodules and study circulating tumor cells. We hypothesized that circulating tumor cells in our ex vivo model will have mesenchymal characteristics. We created the decellularized rat lung scaffold using SDS and Triton-X. We then placed 344SQ or 393P mice lung cancer cell lines in the decellularized rat lung scaffold and perfused them in a customized bioreactor. We measured tumor growth on the scaffold and the number of circulating tumor cells for 14 days. We then analyzed the functional characteristics of the circulating tumor cells using the Boyden chamber and determined gene expression of E-cadherin, N-cadherin, Zeb1 and Twist. Both the 344SQ and 393P lung cancer cell lines formed tumor nodules that gradually increased in size with an increase in the number of circulating tumor cells over the 14-day period in our model. The circulating tumor cells had greater ability to migrate than the monolayer cell cultures in the Boyden chamber assay, with 100% of the circulating tumor cells migrating in contrast to 69% and 71% of the monolayer cell cultures of 344SQ and 393P, respectively. The circulating 393P tumor cells had a significant increase in Twist (58-fold), Zeb (20-fold) and N-cadherin (14-fold) and decrease in E-cadherin compared to the 393P cells from the monolayer cell culture. This difference was even more dramatic for the circulating 344SQ tumor cells with an increase in Twist (&amp;gt;6000-fold), Zeb (14-fold) and N-cadherin (88-fold) compared to the 344SQ cells from the monolayer. There was small 4-fold increase in E-cadherin expression in the circulating 344SQ tumor cells compare to the 344SQ cells from the monolayer. The circulating tumor cells in our model have both phenotypic and genotypic characteristics of mesenchymal cells. The cancer cells that are more mesenchymal at the baseline have a greater difference in these characteristics. The circulating tumor cells in our model may be the sub-population of cells responsible for metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 345. doi:1538-7445.AM2012-345
Notes of a Case of Rheumatic Pericarditis with Tetany
Authors: W. Beattie-Smith
Journal: BMJ (1880)

media.tely, she was seized with -a recurren'e,iof hS 1 f9Hil4blq symptoms, gasping for breath, her pulse 140 a.d upwaxa1sl,.rai4 'ftspjr- ations, blueness of the nails and lips.This fight, for Jlifg cQntirnjedVf9r hours, when she fel-l asleep apparently frorn exbatstiop,i ael 4 Itwlwly the distress subsided; and the leg, which hasd been so swQlon,irapidly returned to nearly its normal dimensions.At that time, there was no repetition of,the evil.; Jbut, fsvrteen months afterwards, the patient, who had continued tQ slifferfrom her pelvic troubles, awoke from sleep with a third r crree;T.isat1ck, which was'sufficiently alarming, btUt not so severe as,the fqrn_rl'asted for about eighteen hours;.and, at a venture, I. tried a jpQdermic ,in- jection of morphia, which appeared decidedly, bene6faL.G,lIly the distress subsided,.andthere was never anotherattgqk.'To summarise: in the case of systemic arterial OlmW m, we had
Cloned mice have an obese phenotype not transmitted to their offspring
Authors: Kellie L.K. Tamashiro, Teruhiko Wakayama, Hidenori Akutsu, Yukiko Yamazaki, Jennifer L. Lachey, Matthew D. Wortman, Randy J. Seeley, David A. D'Alessio, Stephen C. Woods, Ryuzo Yanagimachi, Randall R. Sakai
Journal: Nature Medicine (2002)
Gastric follicular lymphoma with mediastinal lymph node dissemination detected by FDG-PET
Authors: M. Takada, S. Yamamoto
Journal: Endoscopy (2010)

We read with great interest the article by Higuchi et al., ”Impact of double-balloon endoscopy on the diagnosis of jejunoileal involvement in primary intestinal follicular lymphomas: a case series“ [1]. There is no doubt that, as they concluded, double-balloon endoscopy is useful for evaluating the spread of jejunoileal lesions in patients with gastrointestinal follicular lymphoma (GI-FL). In their report, however, the authors stated that fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([18F]FDG-PET) was not useful for the clinical assessment of GI-FL. To show the impact of [18F]FDG-PET on the staging of GI-FL, we report a patient with GI-FL in whom distant dissemination was detected using [18F]FDG-PET.
Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
Authors: Matthew R. Smith, Christopher J. Sweeney, Paul G. Corn, Dana E. Rathkopf, David C. Smith, Maha Hussain, Daniel J. George, Celestia S. Higano, Andrea L. Harzstark, A. Oliver Sartor, Nicholas J. Vogelzang, Michael S. Gordon, Johann S. de Bono, Naomi B. Haas, Christopher J. Logothetis, Aymen Elfiky, Christian Scheffold, A. Douglas Laird, Frauke Schimmoller, Ethan M. Basch, Howard I. Scher
Journal: Journal of Clinical Oncology (2014)

Purpose Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant prostate cancer (CRPC). Patients and Methods Patients received open-label cabozantinib at daily starting doses of 100 mg or 40 mg until disease progression or unacceptable toxicity. The primary end point was bone scan response, defined as ≥ 30% reduction in bone scan lesion area. Other efficacy end points included overall survival, pain, analgesic use, and biomarkers. Results One hundred forty-four patients sequentially enrolled in either a 100-mg (n = 93) or 40-mg (n = 51) study cohort. Ninety-one patients (63%) had a bone scan response, often by week 6. Treatment resulted in clinically meaningful pain relief (57% of patients) and reduction or discontinuation of narcotic analgesics (55% of patients), as well as improvements in measurable soft tissue disease, circulating tumor cells, and bone biomarkers. Improvements in each of these outcomes were observed in both cohorts: bone scan response in 73% and 45%, respectively; reductions in measurable soft tissue disease in 80% and 79%, respectively. Median overall survival was 10.8 months for the entire population. Most common grade 3 or 4 adverse events were fatigue (22%) and hypertension (14%). Fewer dose reductions because of toxicity were required in the 40-mg group. Conclusion The evidence suggests that cabozantinib has clinically meaningful activity in CRPC. Cabozantinib resulted in improvements in bone scans, pain, analgesic use, measurable soft tissue disease, circulating tumor cells, and bone biomarkers. Taken together, these phase II observations warrant further development of cabozantinib in prostate cancer.
Pediatric Neurosurgery: Surgery of the Developing Nervous System
Authors: D. L. Erickson
Journal: JAMA (1984)

This multiauthored text, published under the sponsorship of the Pediatric Section of the American Association of Neurological Surgeons (AANS), represents a contemporary review of the unique problems associated with pediatric neurological surgery. It is the first attempt at a comprehensive treatment of the emerging subspecialty of pediatric neurosurgery since the second edition of Matton's textbook in 1969 and is a much needed and long-awaited work. The scope is wide and the authorship diverse. Each author has reviewed his or her special area of interest, providing the reader with a current and detailed commentary on nearly all aspects of pediatric neurosurgery. The book is generally well written and well organized. A good example of the content is the section on congenital spine problems. The chapters are well organized with a review of basic embryology and anatomy followed by the typical clinical and radiological findings. Surgical treatment is generally well explained and
Abstract 21471: Proteomic Analysis of High Density Lipoprotein (HDL) in Patients With an Acute Coronary Syndrome Reveals a Markedly Changed HDL-Proteome as Compared to Healthy Subjects and Frequent Oxidative Post-Translational Modifications
Authors: Meliana Riwanto, Christian Besler, Lucia Rohrer, Bernd Roschitzki, Arnold von Eckardstein, Thomas F Luescher, Ulf Landmesser
Journal: Circulation (2010)

Background: HDL has been proposed to become dysfunctional in patients with cardiovascular disease, however, the underlying mechanisms remain to be further defined. We used shotgun proteomics to cha...
Simple Method for Achieving Gastric Cooling
Authors: Melvin D. Small, Irving B. Brick
Journal: JAMA (1964)

GASTRIC LAVAGE with iced water has long been used in the management of upper gastrointestinal hemorrhage. The vasoconstrictive effect of cooling and the clinical impression of its efficacy have led to refinements in the technique of cooling and more exact evaluation of its physiological effects.<sup>1-3</sup>Some recent studies<sup>4,5</sup>have shown that an intragastric temperature of 10 C (50 F ) will produce a reduction in perigastric venous outflow, a marked depression in motility, and a significant retardation of gastric emptying. With this physiological support of clinical observations, more widespread use of hypothermia is being made in cases of upper gastrointestinal bleeding. The simplest method of achieving local cooling, gastric lavage with iced water, has certain disadvantages: (1) electrolytes may be eluted, (2) fluid loss into the gut may result in water intoxication, (3) maintenance of an ambient temperature of 10 C is virtually impossible, and (4) constant close supervision
Adoptive Immunotherapy of Experimental Autoimmune Hearing Loss via T Cell Delivery of the IL-12 p40 Subunit
Authors: B. Zhou, M.H. Kermany, Y. Zhou, C. Cai, Q. Cai, I.H. Tarner, C.G. Fathman, P. Kim, J. Kim, W. Liu
Journal: Journal of Allergy and Clinical Immunology (2009)
Abstract 5068: A Prospective Randomized Comparative Trial of Bezafibrate and Pravastatin in Patients with Coronary Artery Disease and High Remnant Lipoprotein Levels
Authors: Keita Sano, Takamitsu Nakamura, Isao Takishima, Aritaka Makino, Mitsumasa Hirano, Yasushi Kodama, Yoshinobu Kitta, Kenichi Kawabata, Junei Obata, Kiyotaka Kugiyama
Journal: Circulation (2008)

Remnant lipoproteinemia is a strong risk factor for atherosclerotic cardiovascular diseases (CVD). However, it remains unclear whether the lowering of remnant lipoprotein levels can prevent CVD events, and it is uncertain which lipid-lowering drug is most effective in reducing remnant lipoprotein levels or CVD events. Thus, this study examined if lowering of remnant lipoprotein levels can reduce CVD risk and which of two common lipid-lowering drugs (fibrate or statin) is more effective. The serum levels of remnant lipoproteins were measured by an immunoseparation method (remnant-like lipoprotein particles cholesterol; RLP-C). This multi-center study recruited 202 patients with chronic coronary artery disease (CAD), high RLP-C levels (≥ 5.0 mg/dL), and mild hypercholesterolemia (≥ 180 and &lt; 260 mg/dL). They were randomly assigned to receive bezafibrate (Beza, 200 ~ 400 mg/day, n = 101) or pravastatin (Prava, 10 ~ 20 mg/day, n = 101), and were prospectively followed-up for 1 year or until the occurrence of a CVD event: cardiac death, nonfatal myocardial infarction, unstable angina pectoris requiring unplanned revascularization, or ischemic stroke. The 2 groups had similar baseline levels of RLP-C (average in total patients, 9.8 ± 0.4 mg/dL), LDL-C (126 ± 6.0 mg/dL), HDL-C (43 ± 1.2 mg/dL), and triglycerides (212 ± 9.7 mg/dL). RLP-C levels at 1 year of treatment were reduced in Beza more than Prava (by - 30% and - 19% from baseline, respectively), whereas reduction of LDL-C levels was less in Beza than Prava (by - 7% and -15%). During follow up, CVD events occurred in 3 patients treated with Beza and in 11 patients with Prava (p = 0.03 by chi-square test) (cardiac death in 0 and 1, unstable angina in 2 and 10, and stroke in 1 and 0, respectively). In a multivariate Cox hazards analysis, reduction of 1-SD (38%) of percent change in RLP-C levels decreased risk of future CVD events by 36% independently of change in LDL-C and HDL-C levels (HR 0.64, 95% CI 0.46 – 0.90, p = 0.01). Bezafibrate therapy decreased RLP-C levels and CVD events to a greater extent than pravastatin in CAD patients with high RLP-C levels and mild hypercholesterolemia. Reduction of remnant lipoprotein levels may improve outcomes in CAD patients with high remnant lipoprotein levels.
ACCORD Glycemia Results Continue to Puzzle
Authors: Edward J. Boyko
Journal: Diabetes Care (2010)

“If I had a world of my own, everything would be nonsense. Nothing would be what it is, because everything would be what it isn't. And contrary wise, what is, it wouldn't be. And what it wouldn't be, it would.”

This quote by Alice from the Disney film version of Alice in Wonderland by Lewis Carroll may make sense in the world she experiences. In our world, Alice's wish is usually not fulfilled, but some findings of the Action to Control Cardiovascular Disease in Diabetes (ACCORD) glycemic control study may be an exception.

The report by Riddle et al. (1) in this issue of Diabetes Care attempts to explain in an observational post hoc analysis of the ACCORD trial whether features of glucose control explain the higher observed death rate in the intensive compared with the standard glycemic control treatment arms (2). All the provisos associated with observational research must be kept in mind when interpreting this analysis, which does not have the same high standard of evidence as testing prespecified hypotheses of a randomized controlled trial. The ACCORD trial assessed the effects of several interventions directed at blood pressure, dysipidemia, and hyperglycemia on diabetes outcomes. The results of the glucose control aspect of the trial defied expectations when it was announced that the intensive glucose control arm was prematurely terminated due to higher mortality associated with assignment to this treatment. …
Can States Take the Lead in Health Care Reform?
Authors: Theodore A. Noel
Journal: JAMA (1993)

<h3>To the Editor.</h3> —I read with interest the article "Can States Take the Lead in Health Care Reform?" by Moon and Holahan.<sup>1</sup>They concede that "states can demonstrate new approaches and take important steps toward improving access and/or containing cost" but continue to the puzzling conclusion that "relying on states alone is unlikely to be the answer to the national problem." This betrays blind faith in an omniscient federal power to solve a problem where individual states have failed. This is the worst possible conclusion. In the effort to make a profit, entrepreneurs compete in the market. The consumer benefits from the smorgasbord of options and prices. Yet many say that health care is not subject to market forces and that the demand is "inelastic." This assumption is wrong, and the truth of the matter lies with three questions. First, "Is 'health care' a single community, or is it a
Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways
Authors: K.E. Nograles, L.C. Zaba, E. Guttman-Yassky, J. Fuentes-Duculan, M. Suárez-Fariñas, I. Cardinale, A. Khatcherian, J. Gonzalez, K.C. Pierson, T.R. White, C. Pensabene, I. Coats, I. Novitskaya, M.A. Lowes, J.G. Krueger
Journal: British Journal of Dermatology (2008)

Background Psoriasis vulgaris is an inflammatory skin disease mediated by Th1 and Th17 cytokines, yet the relative contribution of interferon (IFN)‐γ, interleukin (IL)‐17 and IL‐22 on disease pathogenesis is still unknown. Objectives In this study, we sought to identify the cytokines produced by skin‐resident T cells in normal skin, localize the receptors for these cytokines, and examine how these cytokines alter gene expression profiles of the cells bearing cognate receptors. Methods We used intracellular cytokine staining and flow cytometry to evaluate T cell cytokine production, and immunohistochemistry and double‐label immunofluorescence to localize cytokine receptors in skin. Gene array analysis of cytokine‐treated keratinocytes was performed using moderated paired t‐test controlling for false discovery rate using the Benjamini–Hochberg procedure. Results We demonstrate that T‐helper cells producing IL‐17, IL‐22 and/or IFN‐γ, as well as the cells bearing cognate cytokine receptors, are present in normal human skin. Keratinocytes stimulated with IL‐17 expressed chemokines that were different from those induced by IFN‐γ, probably contributing to the influx of neutrophils, dendritic cells and memory T cells into the psoriatic lesion. In contrast, IL‐22 downregulated genes associated with keratinocyte differentiation and caused epidermal alterations in an organotypic skin model. Conclusions Our results suggest that the Th17 cytokines IL‐17 and IL‐22 mediate distinct downstream pathways that contribute to the psoriatic phenotype: IL‐17 is more proinflammatory, while IL‐22 retards keratinocyte differentiation.
Purple Toes and Coumarin Congeners
Authors: Walter Feder
Journal: JAMA (1965)

To the Editor:—  In their article entitled Petechiae, Ecchymoses, and Necrosis of Skin Induced by Coumarin Congeners ( JAMA  192 : 603-608 [May 17] 1965), Nalbandian et al state that American physicians are almost entirely unaware of the entity. It may be pleasing to think that I belong to an ultraminority aware group, but I don't really believe it.  In differentiating Purple Toes1 from other dermatologic effects of coumarin derivatives, we discussed hermorrhagic necrosis of the skin, and five of the references in our article are identical with those listed by Nalbandian et al. We have personally seen two such cases and have heard about various others; I am sure many other physicians have had similar experiences judging from the correspondence we have received.